{"doi":"10.1111/ene.14612","title":"Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders","abstract":"<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Outcomes of coronavirus disease 2019 (COVID‐19) in patients with neuromyelitis optica spectrum disorders (NMOSD) or myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD), often treated with immunosuppressive therapies, are still unknown.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We conducted a multicenter, retrospective, observational cohort study among all French expert centers for neuromyelitis optica and related disorders. Patients with NMOSD or MOGAD included in the study received a confirmed or highly suspected diagnosis of COVID‐19 between 1 March 2020 and 30 June 2020. Main outcome was COVID‐19 severity score assessed on a seven‐point ordinal scale ranging from 1 (not hospitalized with no limitations on activities) to 7 (death).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Fifteen cases (mean [SD] age: 39.3 [14.3] years, 11 female) were included. Five patients (33.3%) were hospitalized, all receiving rituximab. A 24‐year‐old patient with positive aquaporine‐4 antibody, with obesity as comorbidity, needed mechanical ventilation. Outpatients were receiving anti‐CD20 (5), mycophenolate mofetil (3) or azathioprine (3). They were younger (mean [SD] age: 37.0 [13.4] years), with a longer disease duration (mean [SD]: 8.3 [6.3] years) and had a lower expanded disability severity score (EDSS) score (median [range] EDSS: 2.5 [0–4]) relative to patients requiring hospitalization (mean [SD] age: 44.0 [16.4] years, mean [SD] disease duration: 5.8 [5.5] years, median [range] EDSS: 4 [0–6.5]).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>COVID‐19 outcome was overall favorable in this cohort. Larger international studies are needed to identify risk factors of severe COVID‐19; however, we recommend personal protective measures to reduce risk of SARS‐CoV‐2 infection in this immunocompromised population.</jats:p></jats:sec>","journal":"European Journal of Neurology","year":2021,"id":637423,"datarank":0.47032413238937254,"base_score":3.1354942159291497,"endowment":3.1354942159291497,"self_citation_contribution":0.47032413238937254,"citation_network_contribution":0.0,"self_endowment_contribution":0.47032413238937254,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":22,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":281942,"name":"Élisabeth Maillart","orcid":"0000-0001-7699-0328","position":1,"is_corresponding":false},{"id":1021317,"name":"Caroline Papeix","orcid":"0000-0003-4074-6125","position":2,"is_corresponding":false},{"id":1655112,"name":"Sinead Zeidan","orcid":null,"position":3,"is_corresponding":false},{"id":1021326,"name":"Damien Biotti","orcid":"0000-0003-0569-629X","position":4,"is_corresponding":false},{"id":1655114,"name":"Zoé Lepine","orcid":null,"position":5,"is_corresponding":false},{"id":1655115,"name":"Abir Wahab","orcid":null,"position":6,"is_corresponding":false},{"id":1655116,"name":"Mickael Zedet","orcid":null,"position":7,"is_corresponding":false},{"id":315343,"name":"Pierre Labauge","orcid":"0000-0001-7759-8555","position":8,"is_corresponding":false},{"id":1062740,"name":"Caroline Tilikete","orcid":"0000-0002-1452-1398","position":9,"is_corresponding":false},{"id":848192,"name":"Julie Pique","orcid":"0000-0002-1986-7945","position":10,"is_corresponding":false},{"id":95139,"name":"Ayman Tourbah","orcid":null,"position":11,"is_corresponding":false},{"id":624036,"name":"Guillaume Mathey","orcid":"0000-0002-5747-9169","position":12,"is_corresponding":false},{"id":1655117,"name":"Dalia Dimitri Boulos","orcid":null,"position":13,"is_corresponding":false},{"id":1021323,"name":"Pierre Branger","orcid":"0000-0002-4183-9502","position":14,"is_corresponding":false},{"id":1655118,"name":"Laurent Daniel Kremer","orcid":null,"position":15,"is_corresponding":false},{"id":615864,"name":"Romain Marignier","orcid":"0000-0002-5967-2800","position":16,"is_corresponding":false},{"id":316589,"name":"Nicolas Collongues","orcid":"0000-0002-3683-5582","position":17,"is_corresponding":false},{"id":1655119,"name":"Jérôme De Seze","orcid":null,"position":18,"is_corresponding":false},{"id":1018292,"name":"Céline Louapre","orcid":"0000-0002-4987-1531","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders","abstract":"<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Outcomes of coronavirus disease 2019 (COVID‐19) in patients with neuromyelitis optica spectrum disorders (NMOSD) or myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD), often treated with immunosuppressive therapies, are still unknown.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We conducted a multicenter, retrospective, observational cohort study among all French expert centers for neuromyelitis optica and related disorders. Patients with NMOSD or MOGAD included in the study received a confirmed or highly suspected diagnosis of COVID‐19 between 1 March 2020 and 30 June 2020. Main outcome was COVID‐19 severity score assessed on a seven‐point ordinal scale ranging from 1 (not hospitalized with no limitations on activities) to 7 (death).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Fifteen cases (mean [SD] age: 39.3 [14.3] years, 11 female) were included. Five patients (33.3%) were hospitalized, all receiving rituximab. A 24‐year‐old patient with positive aquaporine‐4 antibody, with obesity as comorbidity, needed mechanical ventilation. Outpatients were receiving anti‐CD20 (5), mycophenolate mofetil (3) or azathioprine (3). They were younger (mean [SD] age: 37.0 [13.4] years), with a longer disease duration (mean [SD]: 8.3 [6.3] years) and had a lower expanded disability severity score (EDSS) score (median [range] EDSS: 2.5 [0–4]) relative to patients requiring hospitalization (mean [SD] age: 44.0 [16.4] years, mean [SD] disease duration: 5.8 [5.5] years, median [range] EDSS: 4 [0–6.5]).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>COVID‐19 outcome was overall favorable in this cohort. Larger international studies are needed to identify risk factors of severe COVID‐19; however, we recommend personal protective measures to reduce risk of SARS‐CoV‐2 infection in this immunocompromised population.</jats:p></jats:sec>","is_dataset_classified":null,"base_score":3.1354942159291497,"endowment":3.1354942159291497,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"33103295","pmcid":null,"openalex_id":"https://openalex.org/W3093477898","authors":[],"funders":[],"total_grants":0,"fwci":2.7908,"citation_percentile":0.9182946,"influential_citations":0,"citation_trend":[{"year":2021,"count":12},{"year":2022,"count":5},{"year":2023,"count":4},{"year":2026,"count":1}],"oa_status":"bronze","license":"http://onlinelibrary.wiley.com/termsAndConditions#vor","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ene.14612","host_type":"journal"},{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ene.14612","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/ene.14612","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/full-xml/10.1111/ene.14612","host_type":"publisher"},{"url":"https://doi.org/10.1111/ene.14612","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/33103295","host_type":"repository"},{"url":"https://hal.umontpellier.fr/hal-03274737","host_type":"repository"}],"fields_of_study":["Multiple Sclerosis Research Studies","Long-Term Effects of COVID-19","Peripheral Neuropathies and Disorders","Adult","Aquaporin 4","COVID-19","Female","Humans","Neuromyelitis Optica","Retrospective Studies","Rituximab","SARS-CoV-2","Young Adult"],"mesh_terms":["Rituximab","COVID-19","SARS-CoV-2","Adult","Female","Humans","Neuromyelitis Optica","Retrospective Studies","Aquaporin 4","Young Adult"],"keywords":["Medicine","Neuromyelitis optica","Azathioprine","Expanded Disability Status Scale","Rituximab","Internal medicine","Pediatrics","Comorbidity","Cohort","Retrospective cohort study","Multiple sclerosis","Disease","Immunology","Immunosuppressant","Nmosd","Covid-19","Mogad"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T18:55:18.141896Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}